Bicara Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCAX Nasdaq 2834 www.bicara.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bicara Therapeutics Inc.

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Dec 15th, 2025 6:00 am
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 - Dec 6th, 2025 6:00 am
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Dec 5th, 2025 11:10 am
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - Dec 1st, 2025 5:00 am
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 10th, 2025 5:30 am
Bicara Therapeutics (BCAX): Valuation Insights Following FDA Breakthrough Therapy Designation for Lead Cancer Treatment - Oct 20th, 2025 6:10 pm
How Investors May Respond To Bicara Therapeutics (BCAX) FDA Breakthrough Therapy Nod for Lead Immunotherapy - Oct 14th, 2025 7:09 am
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - Oct 13th, 2025 5:30 am
Jon Edwards, PhD, Appointed Partner - Oct 1st, 2025 7:00 am
Bicara Therapeutics to Participate in Upcoming Investor Conferences - Aug 27th, 2025 2:01 pm
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Aug 19th, 2025 6:59 am
Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? - Aug 14th, 2025 7:55 am
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 12th, 2025 5:30 am
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Jul 8th, 2025 10:55 pm
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Jun 11th, 2025 2:05 pm
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Jun 3rd, 2025 2:01 pm
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - Jun 1st, 2025 11:12 am
ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer - May 29th, 2025 4:54 am
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - May 27th, 2025 11:59 am
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - May 26th, 2025 7:14 am